108 related articles for article (PubMed ID: 15994163)
1. Challenge in the treatment of estrogen-receptor-negative ductal carcinoma in situ.
Altundag K
J Clin Oncol; 2005 Jul; 23(19):4469-70. PubMed ID: 15994163
[No Abstract] [Full Text] [Related]
2. The role of aromatase inhibitors in the management of ductal carcinoma in situ with an estrogen receptor-positive/progesterone receptor-negative/Her-2/neu receptor-positive pattern.
Altundag K; Bulut N; Sari E; Harputluoglu H
Am J Surg; 2007 Aug; 194(2):272-3. PubMed ID: 17618822
[No Abstract] [Full Text] [Related]
3. Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers.
Ranger GS; Jewell A; Thomas V; Mokbel K
J Surg Oncol; 2004 Nov; 88(2):100-3. PubMed ID: 15499599
[TBL] [Abstract][Full Text] [Related]
4. [Clinicopathologic features and treatment of ductal carcinoma in situ of the breast].
Zhou L; Wang Y; Song X; Du JW; Pei F; Huang LP; Wang WY; Liu ZB; Pan RQ
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3035-8. PubMed ID: 16324401
[TBL] [Abstract][Full Text] [Related]
5. [Prostate carcinoma: higher COX-2 contents in advanced tumors].
Weiss J; Friedrich MG
Aktuelle Urol; 2004 Sep; 35(5):359-61. PubMed ID: 15383996
[No Abstract] [Full Text] [Related]
6. Is it rational to extend the duration of preventive endocrine treatment in hormone receptor positive ductal carcinoma in situ?
Altundag K
J BUON; 2018; 23(3):835. PubMed ID: 30003760
[No Abstract] [Full Text] [Related]
7. [Cylooxgenase-2: a novel molecular target for the prevention and treatment of head and neck cancer on the advance of basic and preclinical research].
Guo W; Zeng QH; Wang CY
Zhonghua Kou Qiang Yi Xue Za Zhi; 2004 May; 39(3):261-3. PubMed ID: 15196405
[No Abstract] [Full Text] [Related]
8. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
9. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
[TBL] [Abstract][Full Text] [Related]
10. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
[TBL] [Abstract][Full Text] [Related]
11. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
[TBL] [Abstract][Full Text] [Related]
12. Some DCIS is different molecularly from DCIS with co-existing IDC.
Steinman S; Bourne P; Yang Q; Tang P; Wang J
Breast J; 2008; 14(1):122-3. PubMed ID: 18186882
[No Abstract] [Full Text] [Related]
13. A new model for ductal carcinoma in situ suggests strategies for treatment.
Gullick WJ
Breast Cancer Res; 2002; 4(5):176-8. PubMed ID: 12223119
[TBL] [Abstract][Full Text] [Related]
14. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
15. Luminal B breast tumors are not HER2 positive.
Bhargava R; Dabbs DJ
Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
[No Abstract] [Full Text] [Related]
16. My most difficult choice.
Saporito B
Time; 2005 May; 165(21):64-5. PubMed ID: 15926776
[No Abstract] [Full Text] [Related]
17. Rationale for use of cyclooxygenase-2 inhibitors in prevention and treatment of bladder cancer.
Pruthi RS; Derksen E; Gaston K; Wallen EM
Urology; 2004 Oct; 64(4):637-42. PubMed ID: 15491687
[No Abstract] [Full Text] [Related]
18. Clinical Vignette. Sciatic nerve entrapment secondary to heterotopic ossification: imaging findings and potential effect of selective cox-2 inhibitors.
Laborde A; Hermier M; Cotton F
Rheumatology (Oxford); 2005 Jan; 44(1):110. PubMed ID: 15611304
[No Abstract] [Full Text] [Related]
19. Role of COX-2 selective inhibitors for prevention and treatment of cancer.
Amir M; Agarwal HK
Pharmazie; 2005 Aug; 60(8):563-70. PubMed ID: 16124396
[TBL] [Abstract][Full Text] [Related]
20. Immunolocalization of liver receptor homologue-1 (LRH-1) in human breast carcinoma: possible regulator of insitu steroidogenesis.
Miki Y; Clyne CD; Suzuki T; Moriya T; Shibuya R; Nakamura Y; Ishida T; Yabuki N; Kitada K; Hayashi S; Sasano H
Cancer Lett; 2006 Nov; 244(1):24-33. PubMed ID: 16427184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
